InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (2 ops.)
Insider track record
Board DirectorDisclosed buys
4
Disclosed sells
2
T+90 hit rate
40%
T+90 mean return
+42.5%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Drutz David, Director. Officer active across 1 company, notably Altimmune, Inc.. In total, 12 reports have been recorded. Breakdown: 4 buys · 2 sells. Total volume traded: €149k. Activity tracked since 19 November 2021. The latest transaction was disclosed on 19 August 2024 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations12 total
20,000 shares@ US$2.6019.1% of flowCommon Stock, par value $0.0001SEC:0001104659-24-091346:0
7,827 shares@ US$6.9319.9% of flowCommon Stock, par value $0.0001SEC:0001104659-24-091346:1
21,750 shares@ US$2.5019.9% of flowCommon Stock, par value $0.0001SEC:0001104659-24-091346:2
8,184 shares@ US$6.8820.6% of flowCommon Stock, par value $0.0001SEC:0001104659-24-091346:3
300 shares@ US$2.8750.3% of flowCommon Stock, par value $0.0001SEC:0001104659-23-092080:0
Ideal exit: 11 May 2024 (T+270)
9,000 shares@ US$4.2714.4% of flowCommon Stock, par value $0.0001SEC:0001104659-23-037190:0
Ideal exit: 18 Dec 2023 (T+270)
139 shares@ US$2.400.1% of flowCommon Stock, par value $0.0001SEC:0001104659-22-120752:0
1,000 shares@ US$8.000.0014% mcap55.2% of flowCommon Stock, par value $0.0001SEC:0001104659-22-072059:0
Ideal exit: 12 Mar 2023 (T+270)
1,200 shares@ US$4.500.0009% mcap36.3% of flowCommon Stock, par value $0.0001SEC:0001104659-22-064786:0
Ideal exit: 18 Feb 2023 (T+270)
70 shares@ US$2.400.0000% mcap1.1% of flowCommon Stock, par value $0.0001SEC:0001104659-22-007911:0
139 shares@ US$2.400.0001% mcap2.1% of flowCommon Stock, par value $0.0001SEC:0001104659-21-150119:0
70 shares@ US$2.400.0000% mcap1.1% of flowCommon Stock, par value $0.0001SEC:0001104659-21-142052:0
12 of 12 declarations
About Drutz David
David Drutz is a Board Member at Altimmune, Inc. He participates in overseeing the company's activities and making strategic decisions. His experience in the biopharmaceutical field allows him to provide valuable insights to the leadership.
